NEW YORK and PETACH TIKVAH, Israel, May 7, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report first quarter 2015 financial results on Thursday, May 14, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. Eastern Time to discuss the results.
Conference Call & Webcast
Thursday, May 14, 2015 at 8:30 a.m. ET/5:30 a.m. PT
Domestic: 888-299-7209
International: 719-325-2244
Conference ID: 9028301
Webcast: http://public.viavid.com/player/index.php?id=114583
Replay
Available through May 28, 2015
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 9028301
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company’s website at www.brainstorm-cell.com.
Logo - http://photos.prnewswire.com/prnh/20141006/150511
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-report-first-quarter-2015-financial-results-on-thursday-may-14-300079507.html
SOURCE BrainStorm Cell Therapeutics Inc.
Help employers find you! Check out all the jobs and post your resume.
